Categories
Business Culture Digital - AI & Apps Lifestyle News Now! Perks Perspectives Sports & Gaming Technology

When Take-Two hit $12B Zynga deal in 2022, casual games peaked, Apple introduced ATT, but mobile game market fell

—  Video-game giant’s push into smartphone titles was expensive and late. 

 

 

Cecilia D’Anastasio / Bloomberg:

 

—  Excitement over the upcoming release of Grand Theft Auto VI is letting publisher Take-Two Interactive Software Inc. deflect investor attention from a big problem: its $12 billion foray into the shrinking mobile-games business.

With just a small presence in the fastest-growing segment of video games — titles played on smartphones — Take-Two splurged last year on Zynga, known originally for Facebook games like FarmVille and Words With Friends. It was the biggest deal ever in video games and boosted revenue from mobile titles to half of Take-Two’s $5.3 billion in annual sales.

 

Unfortunately for Take-Two and longtime Chief Executive Officer Strauss Zelnick, the deal closed just as the mobile-games business was heading into a downturn. With the end of Covid-19 restrictions, consumers who had embraced casual games during the pandemic turned to other diversions. At the same time, Apple Inc. built new privacy features into its software that made it harder for Zynga to attract new players.

“They closed the deal, and the mobile industry spent the next 18 months correcting,” said Doug Creutz, an analyst at Cowen Group who nonetheless recommends buying Take-Two shares because of its other titles, including prospects for GTA VI.

Since the spring of 2022, sales from Zynga’s five highest-grossing games have fallen 23%, according to researcher SensorTower. It’s part of a broad decline in the $90.4 billion mobile-games market that began in 2021 and is expected to let up starting next year, according to researcher NewZoo. Based on Take-Two’s own estimates, Zynga will finish this fiscal year with sales down about 5% from 2021.

 

Mobile Gaming Hits the Skids

Mobile gaming sales will recover slowly from a post-Covid hangover

Source: NewZoo

Zynga’s pipeline offers little encouragement. After putting out an average of seven games a year over the last decade, the company released just three titles in 2023. And just two new releases are on the calendar for the next 12 months, according to Take-Two’s latest earnings report. That includes a Star Wars smartphone game that’s been delayed at least three times

“Our vision for mobile is to be the largest mobile gaming company in the world, based on market share,” Alan Lewis, a company spokesman, said in an email. Take-Two is investing in new intellectual property and has a growing mobile ad business that, he said, “enables us to monetize nearly all of our players, which is a distinguishing characteristic vs. other mobile companies.”

Take-Two was among the last of the major publishers to scoop up a mobile-games company. The Zynga purchase, financed with cash and stock, provided a stable of proven titles. The goal was to prepare the company for the coming hegemony of mobile gaming.

But after soaring to new highs during the pandemic, mobile-gaming revenue fell by 7% industrywide in 2022, according to NewZoo, and is expected to finish 2023 with another 2% drop. Take-Two has lowered projections for Zynga this year, saying in November the division would account for 49% of total bookings — a measure of sales — down from a projected 53% six months earlier.

In May, the company reported $465 million in impairment charges related to Zynga, reflecting the declining outlook for a few titles.

Sheep Parade Through New York City Streets In Celebration Of The Global Launch Of Zynga's FarmVille English Countryside
English farmers and their sheep parade through New York City in celebration of Zynga’s first major FarmVille release, FarmVille English Countryside, in 2011.Photographer: Michael Loccisano/Getty Images

Zynga’s debut in gaming was electric. FarmVille, in which players operate digital farms, shot to internet fame after its release on Facebook in 2009. Some 32 million aspiring farmers logged in every day at the peak. In 2011, FarmVille, Words With Friends and Zynga’s other browser games accounted for 12% of Facebook revenue, according to a filing. Players recruited friends, creating small armies of ad watchers. They could buy tractor fuel or seeds in the game’s general store with FarmVille currency.

But investors couldn’t see a sustainable business model that extended beyond volatile social media or advertising. And Zynga’s games weren’t sticky enough to keep users long term. The company’s initial public offering came off at less than half the $20 billion market value some analysts said was possible. In an Ars Technica report, developers complained that the company’s focus on acquiring new customers and getting them to spend money made the games less fun.

To counter those concerns, Zynga began buying undervalued game companies and moved into mobile. Smartphones were the perfect platform for the company’s strategy of targeting and attracting new players, and eventually encouraging them to buy things in games. From 2015 to 2016, as smartphone ownership swelled, mobile-gaming revenue leapt by $11 billion to $43 billion, according to NewZoo.

Zynga pushed out mobile versions of Words With FriendsFarmVille, and eventually, casino and puzzle games, with the goal of creating “forever franchises.”

Take-Two, meanwhile, had been left behind. In an interview on the Invest Like the Best podcast in October, Zelnick said he underestimated the importance of mobile gaming early on and was focused on Take-Two’s core business of games for consoles.

“I missed the boat,” Zelnick said.

Star Wars: Hunters has been in development since at least 2018 under a team of about 150 — a timeline more typical of a blockbuster console game. Zynga’s BossAlien subsidiary previously made only car-racing games for mobile phones. A complicated arena combat game, Star Wars: Hunters was their first of such scope. And under a multiyear licensing deal with Walt Disney Co., Star Wars: Hunters must clear a certain quality bar while operating on both mobile devices and the Nintendo Switch.

Star Wars: Hunters “continues to hit important milestones as we approach its planned release date in calendar 2024,” Take-Two’s Lewis said, adding that the team developing it has an array of expertise, including in developing console games.

“Profitability in mobile gaming is highly driven by the scale of the game,” Creutz said. “Rather than being dominated by one or two very big games like King, Zynga’s profile has always consisted of about a dozen or so small-to-medium games.”

US-TECHNOLOGY-INTERNET-GAMES-GTA
Zynga’s struggles are overshadowed by the enthusiasm for Grand Theft Auto VI.Photographer: Chris Delmas/AFP/Getty Images

At the same time, the industry is still coping with the privacy changes enacted by Apple. They allowed iPhone users to stop companies like Zynga from tracking their activities. That made it especially hard to identify future players and target them with pitchesMany companies dependent on such marketing tactics were stunned.

“Everyone was freaking out and very concerned about the future of advertising and marketing,” said Eric Kress, host of the Deconstructor of Fun podcast and principal at Gossamer Consulting Group. “Zynga wasn’t ready. They were gonna lose. Take-Two saved them.”

While analysts say the damage from Apple’s move will persist, Zynga said it has adjusted its user acquisition strategy.

But the mobile-game industry has been consolidating ever since. Electronic Arts Inc. acquired Glu Mobile for $2.4 billion in 2021, Take-Two purchased Zynga in 2022 and Savvy Gaming Group bought Scopely for $4.9 billion this past April. And in October, Microsoft Corp. completed the $69 billion purchase of Activision Blizzard Inc., gaining a strong lineup of mobile games in a deal first proposed in 2022.

When analysts ask about Zynga on earnings calls, Zelnick has acknowledged the challenges. Late last year, he described the mobile industry as “soft.” This year, he said, it’s “more challenging than we anticipated.”

Zelnick plans to adapt Take-Two’s most popular franchises to mobile, prompting speculation about a smartphone version of Grand Theft Auto VI. Analysts question whether that’s possible, considering the delays for the Star Wars game. After the acquisition, Zelnick projected $100 million of cost savings within two years, and over $500 million of additional revenue down the line, in part from marketing the mobile games to some of Take-Two traditional customers.

The good news for Take-Two is that Zynga’s struggles are overshadowed by the enthusiasm for Grand Theft Auto VI. Take-Two shares were up 52% this year through Wednesday’s close in New York, triggered by announcements about the new game. They were 1.3% higher at midday Thursday.

“Shareholders were asking, ‘What’s up with Zynga or this downturn in mobile?’” said Joost van Dreunen, a lecturer at New York University’s business school. “Then all of the sudden, Strauss pushes the big, red button in his office and starts issuing Grand Theft Auto commands into the ether.”

(Updates shares. The market value estimate in the 12th paragraph was corrected in an earlier version of this story.)

 

 

Techmeme

Categories
Art & Life Culture Economics International & World Lifestyle News Now! Perspectives

Tony Leung and Andy Lau reunite in ‘The Goldfinger,’ reviving the Hong Kong Noir genre: ‘Epic stories are making a comeback’

“If you really missed not seeing us on screen together, then ‘The Goldfinger’ is your opportunity to do so,” says Hong Kong superstar Andy Lau of his new crime movie where he is again paired with Tony Leung Chiu-wai  “(In the Mood for Love).”

 

The film releases at the end of the month in different parts of Asia and North America (from Dec. 30). Pre-release marketing and promotional efforts make much of the Lau-Leung repairing some twenty years after the “Infernal Affairs” trio of hit movies. The movies were both critical and commercial hits and contained an iconic rooftop scene in Hong Kong’s Wanchai district with the police undercover agent and the mobster’s mole facing off guns drawn.

 

The pair clearly rate each other highly for their acting skills and for the kind of professionalism that has kept them both a the top of the game for more than two decades. If anything, they claim to be getting better. “I think we’ve gotten a lot more mature over the years and we’ve also built up more acting experience,” Leung said.

 

But the real magic – like Quentin Tarantino getting John Travolta to dance again in “Pulp Fiction” – is dropping the pair back into a gritty Hong crime thriller that is drawn on a large and somewhat nostalgic canvas. The director and screenwriter of “The Goldfinger” is Felix Chong, who in recent years is known for “Project Gutenberg” and the series of “Overheard” movies, but who hit the big time at the beginning of the decade as co-writer of “Infernal Affairs.”

 

The new financial crime film pits Lau as a desiccated 1980s crime investigator within the relatively newly formed Independent Commission Against Corruption (ICAC) trying to put Leung as the flamboyant head of the Carmen Century Group behind bars. It is a pursuit that takes many years as, at first, Leung’s character Ching appears to have a Midas touch, building an investment empire through a succession of bold gambles and deft use of shares as a form of payment.

 

When a stock market rout bankrupts the Carmen group, exposing it as little more than a Ponzi scheme, the sleuth thinks he may have his chance. But the body count grows and justice proves hard to deliver. (Part of the story is said to be based on the real world rise and fall of the Carrian Group.)

 

“The Goldfinger” has a complex and fast-moving plot with multiple leaps back and forward in time. And a budget big enough to do justice to the period setting and flavors – it takes in a plethora of Hong Kong locations that were hip and luxurious in their day, but which now look gaudy and deliciously retro.

 

That combination puts “The Goldfinger” in a direct line of succession to Hong Kong noir films such as “Infernal Affairs,” and the oeuvres of Johnny To and John Woo.

 

This is a genre which may have fallen into partial decline as a result of Hong Kong filmmakers decade-long experiment in making films for mainland audiences (and their more restrictive political overseers) and a renewed focus on smaller-budget, hyper-local films. Since 2019, Hong Kong-made films such as “Table for Six,” “Mama’s Affair” and “A Guilty Conscience” have regained market share of the local box office, but failed to convert wide international audiences.

 

“Hong Kong films deserve a bigger market. There have been so many new forms of competition that the [Hong Kong] market has shrunk. At the same time, [Hong Kong films’] subject matter has become been more concerned about local and social topics,” says Lau. “But I also hope to see more epic stories, bigger, more globalized stories that also incorporate local [Hong Kong] elements.”

 

“The theme of financial crimes [such as ‘The Goldfinger’s’] is very attractive and yet very unique. It is something that audiences everywhere in the world can connect with,” said Leung.

 

Hong Kong may no longer the hub of Asian cinema that it was in the 1980s and 1990s, but the skills endure. Leung said that digital de-aging technology was not used and that his character’s three different looks were achieved the old-fashioned way, with wigs, make up and costume. And, as a performer he had little difficulty getting his head around the chronological challenges. “It was all there on the page,” he said.

 

 

 

Variety

Categories
Business Culture Digital - AI & Apps Healthcare Lifestyle News Now! Programs & Events Science Technology

Organon to present at the 42nd Annual J.P. Morgan Healthcare Conference

JERSEY CITY, N.J. — (BUSINESS WIRE) — Organon (NYSE: OGN), announced on Thursday that Kevin Ali, Chief Exec. Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 9, 2024, at 1:30 p.m. PT.

 

Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at: https://jpmorgan.metameetings.net/events/healthcare24/sessions/49500-organon/webcast?gpu_only=true&kiosk=true

 

About Organon

Organon is a global healthcare company formed to focus on improving the health of women throughout their lives. Organon offers more than 60 medicines and products in women’s health in addition to a growing biosimilars business and a large franchise of established medicines across a range of therapeutic areas. Organon’s existing products produce strong cash flows that support investments in innovation and future growth opportunities in women’s health and biosimilars. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

 

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 10,000 employees with headquarters located in Jersey City, New Jersey.

 

For more information, visit http://www.organon.com and connect with us on LinkedIn, Instagram, X (formally known as Twitter) and Facebook.

Contacts

Media:

Karissa Peer

(614) 314-8094

Kate Vossen

(732) 675-8448

Investor:

Jennifer Halchak

(201) 275-2711

Alex Arzeno

(646) 430-2028

Categories
Business Culture Digital - AI & Apps Healthcare Lifestyle News Now! Programs & Events Science Technology

Amneal to participate at the 42nd Annual J.P. Morgan Healthcare Conference

BRIDGEWATER, N.J. — (BUSINESS WIRE) — Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that Chirag Patel, Co-Chief Exec. Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate in the 42nd Annual J.P. Morgan Healthcare Conference on Jan. 9 to 10, 2024.

 

Chirag will present on Jan. 10 at 11:15 a.m. PST, and a live webcast will be accessible on the Company’s website at https://investors.amneal.com. A replay of the webcast will be available for 30 days following the event.

About Amneal

Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully integrated global pharmaceuticals company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of approximately 270 pharmaceutical products, primarily within the United States. In its Generics segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars.

 

In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com.

Contacts

Investor
Anthony DiMeo

Head of Investor Relations

anthony.dimeo@amneal.com

Categories
Business Culture Digital - AI & Apps Energy Government Lifestyle News Now! Perspectives Politics Regulations & Security Science Technology Weather & Environment

Best’s Review looks ahead to 2024 key issues

OLDWICK, N.J. — (BUSINESS WIRE) — In a new article, Best’s Review speaks to experts about what they see as the insurance industry’s top issues in the coming year.

 

Hot topics include natural catastrophes and climate risk, generative artificial intelligence, cyber risk, litigation and nuclear verdicts, as well as the U.S. presidential election.

 

The insurance workforce is also in the spotlight as layoff announcements have accelerated. Read the full story in “Insurers Look Ahead to 2024 and Key Issues: Catastrophes, Inflation, Layoffs, AI and More.”

 

Best’s Review is AM Best’s monthly insurance magazine, covering emerging issues and trends and evaluating their impact on the marketplace. The complete content of Best’s Review is available here.

 

AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit www.ambest.com.

 

Copyright © 2023 by A.M. Best Company, Inc. and/or its affiliates. ALL RIGHTS RESERVED.

Contacts

Patricia Vowinkel
Executive Editor, Best’s Review®
+1 908 882 1771
patricia.vowinkel@ambest.com

Categories
Business Culture Healthcare Lifestyle News Now! Programs & Events Science Technology

MATTER opens applications for accelerator focused on reducing maternal mortality in the US

Health Care Service Corporation, Laerdal Million Lives Fund, BayCare, Parkview Health, University of Chicago Medicine, Organon and Stryker to support cohort of women’s health startups; including $125,000 of investment for each selected company

CHICAGO — (BUSINESS WIRE) — MATTER, the premier healthcare incubator and innovation hub, has opened applications for the second 51 Labs, an accelerator focused on women’s health.

 

This year’s program focuses on preventing maternal mortality in the U.S. before, during and after birth and receives support from Health Care Service Corporation, Laerdal Million Lives Fund, BayCare, Parkview Health, University of Chicago Medicine, Organon and Stryker.

 

Earlier this year, the Centers for Disease Control and Prevention published a report showing that the maternal mortality rate in the U.S. worsened by 40 percent from 2020 to 2021.1 The maternal mortality rate is now the highest in the U.S. since 1965 and is far worse than other industrialized nations.

 

While all ages and races saw an increase in maternal mortality in 2021, many inequities still exist due to a variety of factors, including but not limited to access to quality care, socioeconomic status, race and education level. For example, Black women are three times as likely to die from pregnancy or pregnancy-related causes as white women in the U.S.2

 

“51 Labs is designed to address gaps in investment and innovation in women’s health,” said Steven Collens, CEO of MATTER. “We are pleased to partner with seven key industry stakeholders to help a cohort of startups advance solutions to help address the maternal mortality crisis in the U.S.”

 

The Laerdal Million Lives Fund, a global venture capital fund dedicated to transformative technologies that can help save lives, will serve as a capital partner for this cohort of 51 Labs companies. “Many maternal deaths are preventable. By investing in enabling technologies and digital solutions that can drive early interventions with high life saving potential and quality improvement initiatives, we can help scale companies working in this critical area,” said Becca Shmukler, principal of Laerdal Million Lives Fund.

 

The second cohort of the 51 Labs accelerator will address the question:

 

How can we prevent maternal mortality in the U.S. before, during and after birth?

The program will have three tracks: 1) supporting access to regular prenatal care to identify and mitigate potential risk factors earlier; 2) lowering the incidence of maternal health complications; and 3) supporting mothers during the 12 months after giving birth.

 

“It’s critically important to support innovative solutions to help moms and babies thrive,” said Dr. Monica Berner, chief clinical officer for Health Care Service Corporation. “Earlier this year, HCSC launched an expanded maternal and infant health initiative to improve health outcomes by increasing access to care, reducing care gaps, and educating and engaging residents on a community level. This 51 Labs program is another way we can help support other innovators who are seeking to tackle this critical issue.”

 

Applications for the 12-week accelerator are now open. Participating startups will benefit from one-on-one mentoring with industry experts, workshops, interactive roundtable discussions, forums and more. Additionally, each of the selected companies will receive an investment of $125,000, including $100,000 cash from the Laerdal Million Lives Fund and $25,000 of services from MATTER.

 

The program will culminate with a final showcase in May 2024.

 

For more information, email 51labs@matter.health.

 

About MATTER

At MATTER, we believe collaboration is the best way to improve healthcare. The MATTER collaborative includes more than 800 current and alumni startups from around the world, working together with dozens of hospitals and health systems, universities and industry-leading companies to build the future of healthcare. Together we are accelerating innovation, advancing care and improving lives. For more information, visit matter.health and follow @MATTERhealth.

 

About HCSC

Health Care Service Corporation is the country’s largest customer-owned health insurer, serving more than 18.6 million members in its health plans in Illinois, Montana, New Mexico, Oklahoma and Texas. A Mutual Legal Reserve Company, HCSC is an independent licensee of the Blue Cross and Blue Shield Association.

 

About Laerdal Million Lives Fund

The Million Lives Fund invests in entrepreneurs who are developing and deploying new, emerging technologies capable of saving lives and enhancing healthcare quality and outcomes regardless of demographics or geography. The $100 million fund targets digital health and technology companies whose solutions can improve mortality rates and help reach its goal of helping to save 1 million lives annually by 2030. Investments span across medical education innovations to early interventions, therapeutics and tech-enabled care models. For more information, visit www.laerdalmillionlives.com.

 

About BayCare

BayCare is a leading not-for-profit healthcare system that connects individuals and families to a wide range of services at 16 hospitals and hundreds of other convenient locations throughout the Tampa Bay and central Florida regions. The system is West Central Florida’s largest provider of behavioral health and pediatric services and its provider group, BayCare Medical Group, is one of the largest in the region. BayCare’s diverse network of ambulatory services includes laboratories, imaging, surgical centers, BayCare Urgent Care locations, wellness centers and one of Florida’s largest home care agencies, BayCare HomeCare. Its Medicare Advantage insurance, BayCarePlus, is among the region’s few 5-star-rated plans and the system is ranked in the top 20 percent of large health systems in the country by FORUTNE/Merative™. BayCare’s mission is to improve the health of all it serves through community-owned, health care services that set the standard for high-quality, compassionate care.

 

About Parkview Health

Parkview Health is a not-for-profit, community-based health system serving a northeast Indiana and northwest Ohio population of more than 1.3 million. Parkview Health’s mission is to improve health and inspire well-being in the communities it serves. With more than 16,000 co-workers, it is the region’s largest employer. Parkview Health includes 13 hospitals and an extensive network of primary care and specialty care physicians. The flagship Parkview Regional Medical Center campus includes services such as the Parkview Packnett Family Cancer Institute, Parkview Heart Institute, Samaritan flight and ground transport program, Parkview Ortho Hospital, a certified stroke center, verified adult and pediatric trauma centers, Women’s & Children’s Hospital and an outpatient services center. Parkview has been named one of America’s Best-In-State Employers by Forbes and made Newsweek’s list of Top 100 Most Loved Workplaces.

 

About University of Chicago Medicine

The University of Chicago Medicine, with a history dating back to 1927, is one of the nation’s leading academic medical institutions. UChicago Medicine comprises the University of Chicago Medical Center, which offers a full range of primary and specialty care for adults and children through more than 40 institutes and centers; Ingalls Memorial, a community-based hospital and outpatient facility; a micro-hospital in northwest Indiana, a network of outpatient clinics and physician practices throughout Chicagoland and Northwest Indiana; the Pritzker School of Medicine, one of the top medical schools in the nation; and the University of Chicago Biological Sciences Division, with an affiliated 12 Nobel Prize winners in physiology or medicine.

 

About Organon

Organon is a global healthcare company formed to focus on improving the health of women throughout their lives. Organon offers more than 60 medicines and products in women’s health in addition to a growing biosimilars business and a large franchise of established medicines across a range of therapeutic areas. Organon’s existing products produce strong cash flows that support investments in innovation and future growth opportunities in women’s health and biosimilars. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

 

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 10,000 employees with headquarters located in Jersey City, New Jersey.

 

For more information, visit http://www.organon.com and connect with us on LinkedIn, Instagram, Twitter and Facebook.

 

About Stryker

Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Medical and Surgical, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 130 million patients annually. More information is available at www.stryker.com.

_____________

1Maternal Mortality Rates in the United States, 2021,” Centers for Disease Control and Prevention, 2023.

2U.S. Maternal Mortality Hits Highest Level Since 1965,” The Wall Street Journal, 2023.

Contacts

Julia Cremin

jcremin@pcipr.com
331-333-2928

Categories
Art & Life Business Culture Economics News Now! Programs & Events

Nicole D. Baptiste, IOM named Forty Under 40 Honoree 2023

Alexandria, VA.  — Nicole Baptiste, IOM has been named to the Association of Chamber of Commerce Execs. (ACCE) 2023 Forty Under 40 list of emerging leaders shaping the chamber of commerce industry.

 

This annual recognition program showcases 40 of the industry’s top emerging leaders who have demonstrated success in their careers and made significant contributions to the communities they serve. The list includes CEOs and staff professionals from a wide variety of roles and chamber sizes. Honored for their creativity, dedication and commitment to identifying innovative solutions that will help shape the future of the chamber profession.

 

“I am inspired by these talented professionals who are making a difference in their organizations and the communities they serve,” said ACCE President & CEO Sheree Anne Kelly.

 

“Their passion and dedication not only foster positive change in their regions but also shape a promising future for those they impact.”

 

ACCE has over 1,600 chambers of commerce and related business and economic development organizations as members, representing more than 9,000 professionals in the industry.

 

Eligible chamber professionals must be nominated by their chamber’s president/CEO, direct supervisor or board chair. Candidates must demonstrate meaningful involvement in the advancement of their community and proven professional success within their chamber.

 

Nicole Baptiste joined the African American Chamber of Commerce of New Jersey (AACCNJ) as an Administrative Executive Assistant in 2018. Prior to her employment, she volunteered at the chamber as Adjunct Staff beginning in 2011. She entered into her previous role as Membership Relations and Special Programs Manager in January 2019. Nicole’s areas of responsibility include but are not limited to: special program management, monthly accounts payables and receivables reporting, management of member tracking systems, weekly meetings with members, membership communications and outreach, website management, event website management, webinar platform management/guest coordination and preparation, scheduling of radio show guests for weekly radio show.

 

As Vice President of Membership Acquisition & Financial Administration, Nicole continues to execute the aforementioned responsibilities along with an increased involvement in activities that afford a greater impact towards the growth and sustainability of the AACCNJ.

 

Nicole Baptiste received her IOM designation after completing a four-year Chamber Executive Management Program, at The University of Arizona Tucson, in January 2023. Institute for Organization Management is a professional development program of the U.S. Chamber of Commerce. Graduates receive over 96 hours of course instruction in nonprofit management.

 

“Thank you to the ACCE for recognizing me as an emerging leader in our industry! This achievement is a testament to my hard work and dedication to the AACCNJ. Being acknowledged in this way inspires me to continue working towards achieving my goals and making a positive impact in our community,” says Nicole Baptiste.

 

The full 2023 Forty Under 40 list was announced publicly in the Fall 2023 edition of Chamber Executive, ACCE’s digital magazine. View all the honorees online at https://magazine.acce.org/

 

About the Association of Chamber of Commerce Executives (ACCE)

ACCE is the professional society supporting the people who lead local, regional, statewide and international chambers of commerce and related business and economic development organizations. Our membership includes more than 1,600 business/civic organizations worldwide. We provide our members with information resources, thought leadership, education programs, original research, benchmarking, retirement security, and access to a network of peers. Learn more about us by visiting www.ACCE.org

Categories
Business Culture Economics Healthcare International & World Lifestyle News Now! Science

Merck Animal Health receives positive CVMP opinion for an injectable formulation of BRAVECTO® (Fluralaner) for use in dogs

RAHWAY, N.J. — (BUSINESS WIRE) — Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) issued a positive opinion for BRAVECTO® (fluralaner) 150 mg/ml powder and solvent for suspension for injection for dogs.

 

The CVMP recommends the product for approval for the treatment and persistent killing of fleas (Ctenocephalides felis and Ctenocephalides canis) and ticks (Rhipicephalus sanguineus, Ixodes ricinus, Ixodes hexagonus, and Dermacentor reticulatus) for 12 months. If the European Commission (EC) adopts the recommendation, this injectable formulation of BRAVECTO can be used by or under the supervision of a veterinarian and for administration to dogs and puppies six months of age and older.

 

“Since our initial launch of BRAVECTO nearly a decade ago, Merck Animal Health has been committed to bringing innovations to our customers that protect pets longer from flea and tick infestations and the associated health risks,” said Rick DeLuca, executive vice president and president, Merck Animal Health. “With today’s positive opinion of this injectable formulation of BRAVECTO, the first and only once-yearly injectable flea and tick medication, pet owners are one step closer to a new, convenient option to help ensure year-round comprehensive protection from fleas and ticks without the need for administering multiple doses of medication.”

 

Certain ticks can transmit serious infections in dogs. Many ticks can live in both warm and cold temperatures and are known to feed on dogs,1 making continuous year-round protection of utmost importance for pets and people.

 

“Though people often think of flea and tick season during the summer months, studies have shown that while fleas and ticks are most active from early spring through the fall, they can be a threat year-round,” said Holger Lehmann, vice president, Pharmaceutical Research & Development, Merck Animal Health. “If approved, a once-yearly dosing of BRAVECTO injectable can provide a long duration of protection, simplifying care for both pet owners and veterinarians. This promotes compliance and helps ensure continuous protection.”

 

Based on the CVMP’s recommendation, the EC is expected to issue a decision for marketing authorization in the European Union (EU) during the first quarter of 2024.

 

About BRAVECTO® (fluralaner)

Since its introduction in 2014, BRAVECTO has provided longer-lasting flea and tick protection, with more than 300 million doses distributed in more than 100 countries. BRAVECTO is available in a variety of formulations, including products for both dogs and cats.

 

The flea and tick life cycles can also last for months and missed doses of monthly treatments may leave gaps in protection.

 

Providing pets with continuous flea and tick protection is essential – whether the pet goes outside or not. Contrary to popular belief among pet parents, fleas and ticks are not only active in the spring and summer months, but they are a year-round risk.

 

Fleas and ticks can easily infest dogs and cats. They also can bite and pose health risks to human family members whether at home or outdoors. Ticks can spread serious diseases including rickettsiosis, anaplasmosis and borreliosis (Lyme disease), while fleas are the most common external parasite found on pets and can transmit bartonellosis (Cat Scratch disease) and tapeworms.

 

About Merck Animal Health

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we’ve been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world’s most challenging diseases. Merck Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, is the global animal health business of Merck. Through its commitment to The Science of Healthier Animals®, Merck Animal Health offers veterinarians, farmers, producers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of connected technology that includes identification, traceability and monitoring products. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com and connect with us on LinkedIn, Facebook, X (Formerly Twitter) and Instagram.

 

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA

This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

 

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

 

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2022 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

 

References

[1] Probst J, Springer A, Topp AK, Bröker M, Williams H, Dautel H, Kahl O, Strube C. Winter activity of questing ticks (Ixodes ricinus and Dermacentor reticulatus) in Germany− Evidence from quasi-natural tick plots, field studies and a tick submission study. Ticks and Tick-borne Diseases. 2023 Nov 1;14(6):102225.

Contacts

Media:

Kim Gorode

(973) 255-8904

Kim.Gorode@merck.com

Investor:

Peter Dannenbaum

(732) 594-1579

Categories
Art & Life Business Culture Economics International & World Lifestyle News Now!

Mono Next in Thailand inks deal with Studio Genie of Korea: ATF

Thailand’s broadcast and streaming group Mono Next and Korea’s Studio Genie have struck a deal to collaborate on content creation and distribution.

 

Production of a Thai remake of a Korean series is on the cards, but has not been finalized. The memorandum was announced on stage at the Asia Television Forum in Singapore on Wednesday, with streaming unit Mono Streaming signing on behalf of the Thai group.

 

The on-stage announcement said that a Korean-to-Thai production is a likely product of the deal, but Mono subsequently told Variety that the show has not been identified and that plans are at an early stage.

 

Mono Next includes: free-TV channel Mono 29: Monomax ,an SVOD video streaming platform; and a partnership with 3BB, a Thai broadband provider.

 

In partnership with 3BB, a leading IPTV player, Mono Streaming Company Limited expands across IPTV, free-to-air, and cable channels, emphasizing dedication to diverse content accessibility.

 

“The collaboration between Mono Streaming and KT Studio Genie holds immense potential for creating groundbreaking content that transcends borders,” said Patompong Sirachairat, CEO at Mono Next. “We look forward to exploring new horizons in the entertainment industry together.”

 

“This memorandum of understanding signifies the beginning of a promising partnership between KT Studio Genie and Mono Streaming,” said Kim, Chul Yeon, at KT Studio Genie.

 

Studio Genie is part of the KT Group, formerly known as Korea Telecom, and is an assembly of KT’s media and content businesses. These include StoryWiz (planning, producing and distributing content including webtoons and web novels); Milly’s library (an online reading platform); and music streamer Genie Music. Some 18 months ago, CJ ENM announced that it was buying a stake in the business.

 

 

Variety

Categories
Business Culture Digital - AI & Apps International & World News Now! Programs & Events Technology

Second edition of Emerge development program gets Singapore, Taiwan backing

The Singapore Film Commission and the Taiwan Creative Content Agency (TAICCA) have agreed to back training and development program, Emerge, which supports writers, directors and producers to develop Chinese-language original films.

 

The announcement was unveiled on Friday within the context of the Asia Television Forum (ATF) in Singapore. Signatories included the executive chair of SFC, Justin Ang and chairperson of TAICCA, Homme Tsai.

 

The 12-week programme will combine hybrid and virtual sessions held in both Singapore and Taiwan from March to May 2024. In-person classes are scheduled to take place in Singapore in March, hybrid workshops and consultations online and in Taiwan, culminating in a final pitch day and award ceremony, planned at the Marche du Film Market in Cannes, May.

 

The session will include experienced global film producers, directors and executives including Ron Howard, Sukee Chew (“Sugar23”), Trey Callaway (“9-1-1 Lonestar”), Derek Tsang (“Better Days”) and Jojo Hui (“The Warlords”) as guest lecturers.

 

This is the second edition of Emerge, after a previous round backed by TAICCA, Ron Howard and Brian Grazer’s Imagine Entertainment and Cora Yim’s Sixty Percent Productions.

 

“With the increasing demand for Asian storytelling all over the world, this collaboration provides a truly international platform for Singapore filmmakers to take their skills to the next level,” said Ang.

 

“Leveraging the resources of Hollywood and leading multinational film and television companies in Asia, the collaboration seeks to craft content that resonates on a global scale,” said TAICCA chair Homme Tsai.

 

“We had a successful inaugural Emerge with TAICCA and Sixty Percent Productions, which allowed us to work with talented storytellers that yielded results,” said Imagine executive chairmen Grazer and Howard, in a joint statement.

 

“Emerge has been fruitful since its launch last September, with five Taiwanese TV projects incubated and a TV series [Chang Kaichih and Chen Fang Chi’s “Gunshot”] greenlit by Public Television Service in Taiwan for further development. We are delighted to extend our program to developing films with filmmakers from Singapore,” said Yim.

 

 

Variety